FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096294164> ?p ?o ?g. }

• W2096294164 endingPage "260" @default.
• W2096294164 startingPage "253" @default.
• W2096294164 abstract "In Alzheimer's disease (AD), the involvement of cholinergic deficit and overstimulation of N-methyl-D-aspartate (NMDA) receptors by excessively released glutamate has been proposed. Since no existing drug currently addresses both pathologies, a combination therapy may be used clinically to target both mechanisms. The objective of the current study was to determine whether the NMDA receptor antagonist, neramexane affects the acetylcholinesterase (AChE) inhibition produced by donepezil and rivastigmine, two drugs used in the treatment of AD, or a prototype organophosphate compound diisopropylphosphorofluoridate (DFP) in rat cortex, hippocampus, striatum, and brainstem. Neramexane, at therapeutically relevant or higher doses (3.1, 6.2, or 12.4 mg/kg, ip), did not produce any apparent behavioral toxicity. Donepezil (0.75 mg/kg, ip), rivastigmine (0.35 mg/kg, ip) or DFP (1.5 mg/kg, ip) were administered at doses that produced approximately 50% inhibition of AChE and were well tolerated. Also, neramexane in combination with either of the AChE inhibitors did not produce any behavioral toxicity. This magnitude of AChE inhibition has been shown to increase extracellular acetylcholine (ACh) concentrations to therapeutically relevant levels. Neramexane (12.4 mg/kg) did not inhibit AChE activity in any of the brain regions tested when evaluated over a 24-h period. Rats receiving neramexane alone or in combination with an AChE inhibitor (donepezil, rivastigmine, or DFP) were sacrificed 60 min after neramexane or DFP, 15 min after donepezil, and 30 min after rivastigmine administration. The times at which drug (donepezil, rivastigmine, or DFP) effects were assessed were based on maximal AChE inhibition established from previously reported time course studies. The current findings indicate that neramexane alone did not affect AChE activity at any dose tested nor did it influence the AChE inhibition produced by donepezil or rivastigmine in any brain region examined. However, a low dose of neramexane (3.1 mg/kg) significantly attenuated the inhibition of AChE produced by DFP in the hippocampus, striatum and brainstem, while higher doses (6.2 or 12.4 mg/kg) attenuated DFP-induced AChE inhibition in all four of the brain regions evaluated. These results suggest that AChE inhibition produced by donepezil or rivastigmine is not altered by the co-administration of neramexane. Drug Dev Res 68:253–260, 2007. © 2007 Wiley-Liss, Inc." @default.
• W2096294164 created "2016-06-24" @default.
• W2096294164 creator A5035745030 @default.
• W2096294164 creator A5067591694 @default.
• W2096294164 date "2007-01-01" @default.
• W2096294164 modified "2023-09-28" @default.
• W2096294164 title "Donepezil- or rivastigmine-induced acetylcholinesterase inactivation is not modulated by neramexane in rat brain" @default.
• W2096294164 cites W1541346279 @default.
• W2096294164 cites W1964787009 @default.
• W2096294164 cites W1974758049 @default.
• W2096294164 cites W1976250892 @default.
• W2096294164 cites W1976491350 @default.
• W2096294164 cites W1977755787 @default.
• W2096294164 cites W1978581754 @default.
• W2096294164 cites W1981480090 @default.
• W2096294164 cites W1982259828 @default.
• W2096294164 cites W1985215852 @default.
• W2096294164 cites W1988940766 @default.
• W2096294164 cites W1993788242 @default.
• W2096294164 cites W1994067502 @default.
• W2096294164 cites W1997886955 @default.
• W2096294164 cites W2011098517 @default.
• W2096294164 cites W2012668922 @default.
• W2096294164 cites W2014091144 @default.
• W2096294164 cites W2015877664 @default.
• W2096294164 cites W2019720355 @default.
• W2096294164 cites W2021170634 @default.
• W2096294164 cites W2021280501 @default.
• W2096294164 cites W2024623973 @default.
• W2096294164 cites W2024673430 @default.
• W2096294164 cites W2028855883 @default.
• W2096294164 cites W2037986700 @default.
• W2096294164 cites W2041513819 @default.
• W2096294164 cites W2048006402 @default.
• W2096294164 cites W2055740811 @default.
• W2096294164 cites W2056323706 @default.
• W2096294164 cites W2072266566 @default.
• W2096294164 cites W2075356278 @default.
• W2096294164 cites W2076676029 @default.
• W2096294164 cites W2081044883 @default.
• W2096294164 cites W2083055664 @default.
• W2096294164 cites W2092356280 @default.
• W2096294164 cites W2093345349 @default.
• W2096294164 cites W2107327698 @default.
• W2096294164 cites W2117396078 @default.
• W2096294164 cites W2132806643 @default.
• W2096294164 cites W2152116430 @default.
• W2096294164 cites W2162134510 @default.
• W2096294164 cites W2163186438 @default.
• W2096294164 cites W2166070786 @default.
• W2096294164 cites W2209078744 @default.
• W2096294164 cites W3023984377 @default.
• W2096294164 cites W4232706823 @default.
• W2096294164 cites W4246302366 @default.
• W2096294164 cites W4366345816 @default.
• W2096294164 doi "https://doi.org/10.1002/ddr.20186" @default.
• W2096294164 hasPublicationYear "2007" @default.
• W2096294164 type Work @default.
• W2096294164 sameAs 2096294164 @default.
• W2096294164 citedByCount "6" @default.
• W2096294164 countsByYear W20962941642018 @default.
• W2096294164 countsByYear W20962941642019 @default.
• W2096294164 countsByYear W20962941642020 @default.
• W2096294164 crossrefType "journal-article" @default.
• W2096294164 hasAuthorship W2096294164A5035745030 @default.
• W2096294164 hasAuthorship W2096294164A5067591694 @default.
• W2096294164 hasConcept C126322002 @default.
• W2096294164 hasConcept C170493617 @default.
• W2096294164 hasConcept C181199279 @default.
• W2096294164 hasConcept C185592680 @default.
• W2096294164 hasConcept C22885893 @default.
• W2096294164 hasConcept C2775910092 @default.
• W2096294164 hasConcept C2776332859 @default.
• W2096294164 hasConcept C2776885963 @default.
• W2096294164 hasConcept C2777836312 @default.
• W2096294164 hasConcept C2778816929 @default.
• W2096294164 hasConcept C2779134260 @default.
• W2096294164 hasConcept C2779483572 @default.
• W2096294164 hasConcept C2779484449 @default.
• W2096294164 hasConcept C2780904820 @default.
• W2096294164 hasConcept C31896038 @default.
• W2096294164 hasConcept C55493867 @default.
• W2096294164 hasConcept C67018056 @default.
• W2096294164 hasConcept C71924100 @default.
• W2096294164 hasConcept C98274493 @default.
• W2096294164 hasConceptScore W2096294164C126322002 @default.
• W2096294164 hasConceptScore W2096294164C170493617 @default.
• W2096294164 hasConceptScore W2096294164C181199279 @default.
• W2096294164 hasConceptScore W2096294164C185592680 @default.
• W2096294164 hasConceptScore W2096294164C22885893 @default.
• W2096294164 hasConceptScore W2096294164C2775910092 @default.
• W2096294164 hasConceptScore W2096294164C2776332859 @default.
• W2096294164 hasConceptScore W2096294164C2776885963 @default.
• W2096294164 hasConceptScore W2096294164C2777836312 @default.
• W2096294164 hasConceptScore W2096294164C2778816929 @default.
• W2096294164 hasConceptScore W2096294164C2779134260 @default.
• W2096294164 hasConceptScore W2096294164C2779483572 @default.
• W2096294164 hasConceptScore W2096294164C2779484449 @default.

• next